Project Grant R01AI201261
Award Date 8/18/26
Completion Date 7/31/31
Dollars Obligated $747K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Huntsville, AL 35899, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Alabama at Birmingham $1,173,450 on September 18, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structure-function relationships of influenza non-structural protein 1 (NS1) and nuclear export protein (NEP) that govern the influenza virus lifecycle. The research will define mechanistic and structural understanding of how NS1 and NEP accomplish their viral...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $437,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a predictive computational model of Eastern Equine Encephalitis Virus (EEEV) replication dynamics in host cells. The recipient will use advanced experimental tools—including single-molecule FISH, ribosome profiling, digital droplet RT-PCR, and reporter viruses—to quantitatively map EEEV...
- The National Institute of Allergy and Infectious Diseases awarded the University of Alabama at Birmingham $744,991 on August 1, 2026, to develop a community knowledgebase supporting virus taxonomy research under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funded work centers on creating a taxonomic database, website, and supporting tools focused on virus classification and nomenclature maintained by the International Committee on Taxonomy of Viruses (ICTV). The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University a Project Grant of $155,454 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025, through July 31, 2027. This award funds research to identify and characterize molecular mechanisms of Venezuelan Equine Encephalitis Virus (VEEV) entry into host cells and to develop enhanced therapeutic interventions targeting...
- The National Institute of Allergy and Infectious Diseases awarded the University of Alabama at Birmingham $490,611 on April 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of regulatory dendritic cells in neonatal immune responses to influenza infection. The research examines how a newly identified form of dendritic cell maturation (mREGDC1) impairs protective CD8 T cell responses in newborns and young infants during respiratory viral...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, College Park $1,575,599 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct structural and biochemical characterization of hepatitis C virus E1E2 glycoproteins critical for vaccine development. The research addresses the global burden of at least 58 million hepatitis C virus infections and an annual rate of 1–2 million new infections. While...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $264,633 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize antivirals against poxviruses. The funded work advances preclinical development of modified carbocyclic nucleoside analogs targeting monkeypox virus (MPXV) and vaccinia virus (VACV). The research team identified a lead compound demonstrating potency of 187 nanomolar...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $149,035 on May 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund Project Grant K99AI196249. The award funds research into glycosylation as a host defense mechanism against alphaviruses. The research integrates biochemical, cell biological, and glycan-based approaches to define how the enzyme B3GNT2 (β1,3-N-acetylglucosaminyltransferase...
- The National Institute of Allergy and Infectious Diseases awarded Auburn University $439,335 on July 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct comparative immunological research using wild-derived and laboratory mice as vaccine development models. The project addresses the poor translation of nanoparticle vaccine formulations from preclinical mouse studies to human clinical trials, where only approximately 10 percent of treatments succeed....
- The National Institute of Allergy and Infectious Diseases awarded Emory University $160,448 on March 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and validate mutations in orthopoxviruses that confer resistance to acyclic phosphonates, characterize the biochemical mechanisms of inhibition by and resistance to these compounds, and evaluate combination therapies to prevent resistance emergence. The research responds to the 2022 global mpox...